Humans | Rodents | |
---|---|---|
System | - alterations on the mesocorticolimbic system [15, 16]. - thicker prefrontal cortex [43]. | - changes in the dopaminergic activity of the corpus striatum and on the prefrontal cortex [21]. - dopaminergic activity of the hypothalamic–pituitary axis and the amygdala [13]. - alterations in the cortical glutamatergic system and affects the migration of glutamatergic neurons and GABAergic interneurons [22, 23]. - alterations in the intrinsic electrophysiological properties of the Purkinje neurons of the cerebellum [24]. |
Molecular | - high CB1 mRNA expression in the fetal hippocampus and amygdala [15]. - decrease in the expression of proenkephalin mRNA in the fetal striatum with a dose-dependent effect [20, 47]. - up-regulation of proenkephalin mRNA in the mesolimbic area in adult life [20, 47]. - increased expression of u-opioids in the amygdala [17,18,19,20, 47]. - decrease of k-opioid receptor mRNA in the mid-dorsal thalamus [17,18,19,20, 47]. |